Guanabenz

Last updated
Guanabenz
Guanabenz.svg
Guanabenz sf.png
Clinical data
Trade names Wytensin
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a686003
ATC code
  • none
Pharmacokinetic data
Protein binding 90%
Elimination half-life 6 hours
Identifiers
  • 2-(2,6-dichlorobenzylidene)hydrazinecarboximidamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.023.410 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C8H8Cl2N4
Molar mass 231.08 g·mol−1
3D model (JSmol)
  • Clc1cccc(Cl)c1\C=N\N=C(/N)N
  • InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+ Yes check.svgY
  • Key:WDZVGELJXXEGPV-YIXHJXPBSA-N Yes check.svgY
   (verify)

Guanabenz (pronounced GWAHN-a-benz, sold under the trade name Wytensin) is an alpha agonist that is selective to the alpha-2 adrenergic receptor. Guanabenz is used as an antihypertensive drug used in the treatment of high blood pressure (hypertension). [1] [2]

Contents

The most common side effects during guanabenz therapy are dizziness, drowsiness, dry mouth, headache and weakness. [3]

Guanabenz can make one drowsy or less alert, therefore driving or operating dangerous machinery is not recommended.

Research

Guanabenz also has some anti-inflammatory properties in different pathological situations, including multiple sclerosis. [4]

Guanabenz was found in one study to exert an inhibitory effect by decreasing the abundance of the enzyme CH25H, a cholesterol hydroxylase linked to antiviral immunity. Therefore, it is suggested that the drug and similar compounds could be used to treat type I interferon-dependent pathologies and that the CH25H enzyme could be a therapeutic target to control these diseases, [5] including amyotrophic lateral sclerosis.

See also

References

  1. ↑ Walker BR, Hare LE, Deitch MW (1982). "Comparative antihypertensive effects of guanabenz and clonidine". The Journal of International Medical Research. 10 (1): 6–14. doi:10.1177/030006058201000102. PMID   7037502. S2CID   2139809.[ permanent dead link ]
  2. ↑ Bonham AC, Trapani AJ, Portis LR, Brody MJ (December 1984). "Studies on the mechanism of the central antihypertensive effect of guanabenz and clonidine". Journal of Hypertension Supplement. 2 (3): S543 –S546. PMID   6599714.[ permanent dead link ]
  3. ↑ "Guanabenz | The Merck Index Online". www.rsc.org. Retrieved 2023-04-17.
  4. ↑ Way SW, Podojil JR, Clayton BL, Zaremba A, Collins TL, Kunjamma RB, et al. (March 2015). "Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic". Nature Communications. 6: 6532. Bibcode:2015NatCo...6.6532W. doi:10.1038/ncomms7532. PMC   4360920 . PMID   25766071.
  5. ↑ Perego J, Mendes A, Bourbon C, Camosseto V, Combes A, Liu H, et al. (January 2018). "Guanabenz inhibits TLR9 signaling through a pathway that is independent of eIF2α dephosphorylation by the GADD34/PP1c complex". Science Signaling. 11 (514) eaam8104. doi:10.1126/scisignal.aam8104. hdl: 10773/27856 . PMID   29363586. S2CID   13680678.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.